ALGS Company Profile and Key Details

Q: Who are the executives of ALGS?

Dr. Leonid Beigelman Ph.D.Pres & DirectorMs. Lucinda Y. Quan J.D.Executive Vice President, Chief Bus. Officer & Gen. CounselDr. Lawrence M. Blatt MBA, Ph.D.Chief Executive Officer & ChairmanDr. Julian A. Symons DPHILExecutive Vice President & Chief Scientific OfficerKristina EngesethVice President and Head of People & CultureMr. John FryExecutive Vice President of Clinical Devel.Dr. David B. Smith Ph.D.Executive Vice President & Head of Chemical OperationsDr. Matthew W. McClure M.D.Executive Vice President & Chief Medical OfficerDr. Sushmita M. Chanda DABT, Ph.D.Executive Vice President of Translational Safety SciencesMs. Lesley Ann Calhoun CPAExecutive Vice President & Chief Financial OfficerDr. Tse-I Lin Ph.D.Vice President of Early Compound Devel. & Belgian Site Head

NASDAQ : ALGS

Aligos Therapeutics

$6.49

-0.58-8.20%

At Close 4:00 PM

$6.08

−0.41-6.32%

After-Market 08:30 PM

58.98

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Aligos Therapeutics, Inc. (ALGS) stock declined over -8.20%, trading at $6.49 on NASDAQ, down from the previous close of $7.07. The stock opened at $7.02, fluctuating between $6.49 and $7.17 in the recent session.

Stock Snapshot

7.07

Prev. Close

39.94M

Market Cap

6.49

Day Low

-0.48

P/E Ratio

-13.54

EPS (TTM)

-0.62

Cash Flow per Share

7.02

Open

6.15M

Number of Shares

7.1651

Day High

69.31%

Free Float in %

0.73

Book Value

70.46K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	7.02	7.17	6.49	6.49	71K
Feb 04, 2026	7.50	8.00	6.81	7.07	52.83K
Feb 03, 2026	7.94	8.31	7.23	7.52	55.49K
Feb 02, 2026	7.98	8.39	7.76	7.95	80.89K
Jan 30, 2026	7.89	8.15	7.70	8.07	40.15K
Jan 29, 2026	8.13	8.17	7.70	8.12	49.45K
Jan 28, 2026	8.69	8.95	8.06	8.06	79.41K
Jan 27, 2026	8.40	8.66	7.97	8.59	93.38K
Jan 26, 2026	8.04	8.49	7.92	8.39	77.63K
Jan 23, 2026	8.87	8.99	8.02	8.12	157.41K
Jan 22, 2026	7.94	8.81	7.94	8.54	123.68K
Jan 21, 2026	8.13	8.99	7.77	8.00	80.38K
Jan 20, 2026	7.69	8.29	7.61	8.01	83.63K
Jan 16, 2026	8.29	8.64	7.94	7.94	64.83K
Jan 15, 2026	9.02	9.39	8.20	8.26	86.96K
Jan 14, 2026	9.23	9.34	8.80	9.05	86.69K
Jan 13, 2026	8.59	9.43	8.52	9.24	47.49K
Jan 12, 2026	9.00	9.07	8.39	8.71	109.98K
Jan 09, 2026	10.41	10.45	9.00	9.00	87.96K
Jan 08, 2026	9.65	10.49	9.61	10.33	88.76K

Contact Details

South San Francisco, CA 94080

United States

https://www.aligos.com 800 466 6059

About Company

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-� agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Stock Peers

ARGX

-30.56-3.59%

argenx SE$820.31 REGN

-8.645-1.12%

Regeneron Pharmaceuticals, Inc.$766.63 UTHR

-3.66-0.76%

United Therapeutics Corporation$478.93 MDGL

-15.19-3.17%

Madrigal Pharmaceuticals, Inc.$463.42 VRTX

-11.71-2.49%

Vertex Pharmaceuticals Incorporated$458.81 ALNY

-20.72-5.89%

Alnylam Pharmaceuticals, Inc.$331.24 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

2.28+0.75%

Praxis Precision Medicines, Inc.$305.62 KRYS

-1.49-0.55%

Krystal Biotech, Inc.$267.64 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Aligos Therapeutics, Inc. (NASDAQ:ALGS) closed at $6.49 USD, losing -$0.58 (-8.20%) from the previous close of $7.07. The stock is currently mid-range between its 52-week high and low $3.76 and $29.54. With a market capitalization of about $39.94 million, Aligos Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.66). Key stats such as the average daily volume over the past year has been around 75.44 thousand shares, in line with its 52-week average. Headquartered in South San Francisco, CA, Aligos Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Lawrence Blatt, the company employs approximately 70 people and listed since October 16, 2020. Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.

Technical Performance

ALGS has shown weak momentum, losing -8.04% over the past week and -19.82% over the past quarter, though year-to-date performance is down -14.06%. Short-term trend indicators are mixed aligned (SMA20 -21.55%, SMA50 -31.11%, SMA200 -23.09%). The stock’s 14-day RSI is 31.02 (weak momentum), while the ATR of 0.84 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -78.03% below its high and over 72.61% above its low. Average 10-day trading volume of 66.69 thousand shares is below the 3-month average of 76.63 thousand, indicating normal recent market interest.

Valuation Metrics

Aligos Therapeutics, Inc. trades at a P/E ratio of -0.8, slightly below the S&P 500 average, with a price-to-sales ratio of 15.51 and a price-to-book ratio of 0.96 suggesting the stock is closer to book value. The P/FCF stands at -0.52, also above market averages.

Dividend & Fair Value

Aligos Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.01. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 32.73% annually over the next five years. The latest quarter delivered EPS of -$3.04. The next quarter is forecast at -$2.49. Next year's EPS is expected at $31.29. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $70.00 to $20.00. The high target offers 978.58% upside. The low target suggests 208.17% downside. The mean target is $52.00. This offers 701.23% upside. Aligos Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 45.45%. The prior quarter beat by -34.89%. Over the last six quarters, Apple has recorded several small beats. These include -118.75% in August 06, 2024.

Shareholding & Insider Activity

Aligos Therapeutics, Inc. has 5.35 million shares outstanding. The public float is 3.14 million shares, elevated short interest at 5.13% of float. This equals 268.94 thousand shares. The short ratio is 3.91 days. Institutional investors hold 59.25% of the float. Insiders own 10.37%. Nuechterlein Carole holds 3.97 million shares, Novo Holdings A/S has 2.61 million shares and Versant Venture Capital VI, L.P. has 862.44 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Aligos Therapeutics generated $15.53M in revenue, or $0.24 per share. Gross margin was 80.24%, operating margin -562.99%, and net profit margin -564.61%. Returns are negative, with ROA at -56.97% and ROE at -95.22%.
On valuation metrics, Aligos Therapeutics trades at a P/E of -0.80, P/S of 15.51 and P/B of 0.96. The current ratio is 4.70 and quick ratio is 4.70. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -6554.50 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.08, supported by a cash flow-to-debt ratio of -13.05.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Aligos Therapeutics posted revenue of $15.53M, down slightly from $13.91M in the prior quarter. Gross profit was $12.46M (margin 80.24%). Operating income was - $87.43M (margin -563.0%). Net income was- $87.68M (EPS - $1.36).
The company ended the quarter with $135.77M in cash and short-term investments, a total debt of $11.14M, and net debt of - $124.64M. Total assets were $153.90M, with equity of $92.08M. Financials further reflected weakness, with operating cash flow of - $79.00M, free cash flow of - $79.02M, and capital expenditures of - $19.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Aligos Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.78%, with price expected at $6.05 by February 19, 2026, within a range of $5.52 to $6.56 3-Month Outlook: Projected fall of -62.4%, reaching $2.44 by May 05, 2026, with a range of $1.63 to $3.18. 1-Year Outlook: Projected gain of 78.43%, with price at $11.58 by February 05, 2027, within a range of $0.00 to $19.12.

Key Takeaways

Aligos Therapeutics, Inc. (NASDAQ:ALGS) shares are down -14.06% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Aligos Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.8. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $36.60, suggesting 463.94% upside. Our AI forecast model points to short-term weakness (-6.78% over two weeks), a medium-term fall (-62.4% over three months), and a longer-term gain (78.43% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Aligos Therapeutics, Inc. (ALGS) stock price?

Aligos Therapeutics, Inc. (NASDAQ: ALGS) stock price is $6.49 in the last trading session. During the trading session, ALGS stock reached the peak price of $7.17 while $6.49 was the lowest point it dropped to. The percentage change in ALGS stock occurred in the recent session was -8.2% while the dollar amount for the price change in ALGS stock was - $0.58.

ALGS's industry and sector of operation?

The NASDAQ listed ALGS is part of Biotechnology industry that operates in the broader Healthcare sector. Aligos Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ALGS?

Dr. Leonid Beigelman Ph.D.
Pres & Director
Ms. Lucinda Y. Quan J.D.
Executive Vice President, Chief Bus. Officer & Gen. Counsel
Dr. Lawrence M. Blatt MBA, Ph.D.
Chief Executive Officer & Chairman
Dr. Julian A. Symons DPHIL
Executive Vice President & Chief Scientific Officer
Kristina Engeseth
Vice President and Head of People & Culture
Mr. John Fry
Executive Vice President of Clinical Devel.
Dr. David B. Smith Ph.D.
Executive Vice President & Head of Chemical Operations
Dr. Matthew W. McClure M.D.
Executive Vice President & Chief Medical Officer
Dr. Sushmita M. Chanda DABT, Ph.D.
Executive Vice President of Translational Safety Sciences
Ms. Lesley Ann Calhoun CPA
Executive Vice President & Chief Financial Officer
Dr. Tse-I Lin Ph.D.
Vice President of Early Compound Devel. & Belgian Site Head

How ALGS did perform over past 52-week?

ALGS's closing price is 72.61% higher than its 52-week low of $3.76 where as its distance from 52-week high of $29.54 is -78.03%.

How many employees does ALGS have?

Number of ALGS employees currently stands at 70.

Link for ALGS official website?

Official Website of ALGS is: https://www.aligos.com

How do I contact ALGS?

ALGS could be contacted at phone 800 466 6059 and can also be accessed through its website. ALGS operates from One Corporate Drive, South San Francisco, CA 94080, United States.

How many shares of ALGS are traded daily?

ALGS stock volume for the day was 70.46K shares. The average number of ALGS shares traded daily for last 3 months was 75.44K.

What is the market cap of ALGS currently?

The market value of ALGS currently stands at $39.94M with its latest stock price at $6.49 and 6.15M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	70
Beta	2.65
Sales or Revenue	$15.53M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ALGS Company Profile and Key Details

Aligos Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Valuation Metrics